Top of the morning to you. And a fine one it is, yes? There is nothing like a busy start to the day to make you feel invigorated. We will be busier than usual, though, today because we must break later for a meeting. We apologize for the interruption in service, but trust you understand. Meanwhile, let us now enjoy a delicious cup of stimulation and peruse some items of interest. Hope your day goes well and see you soon...
Generics Grab 15 Percent Of Lipitor Market So Far (Dow Jones)
Sebelius Says Teva Can Reapply To End Plan B Pill Limits (Bloomberg News)
Hospira Chairman Says He Did Not Resign Under Pressure (InPharma Technologist)
Some Depressed People Do Worse On Drugs: Study (Reuters)
J&J To Release Additional Supply Of Doxil Cancer Drug (Dow Jones)
AVI Biopharma Lays Off 28 Percent Of Staff (Xconomy)
Takeda Drug Cuts Myeloma Death In Five-Year Study (Reuters)
Novartis Site Is First Cell-Based Flu Plant In US (MedCity News)
FTC OKs Valent Acquisition But Requires Asset Sales (Reuters)
EDITOR'S NOTE: Please check this post for updates throughout the morning
1 Comment
so, Sebelius says Teva can reapply? how does this work, exactly? do they send their application to her for approval? or send it to the same FDA that approved it last time? is Sebelius now the de-facto FDA?